Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

About this update from Aspire Biopharma Holdings, Inc.

[{"type":"text","content":"ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application - which seeks patent protection of Aspire's proprietary technology in a variety of classes of drugs and other substances--focuses exclusively on protecting the Company's advanced sublingual drug delivery system, which is designed to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients ("APIs") and other substances into the bloodstream, increasing bioavailability and improving speed of onset.","length":814,"tagName":"p"},{"type":"text","content":"An omnibus claim is a statement in a patent application that describes the unique features of an invention and defines the scope of protection for the patent. It is a formal way of summarizing the points of novelty of the invention and is usually followed by a fixed form. The omnibus patent can provide IP protection in new areas/classes in addition to the patents already filed by Aspire.","length":390,"tagName":"p"},{"type":"text","content":"The Aspire sublingual delivery platform represents a significant advancement in drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredients (APIs) and addressing critical challenges in both local and systemic drug delivery. The omnibus patent application underscores Aspire's commitment to securing comprehensive intellectual property protection for its innovative technology in a variety of product areas beyond the patents already filed, which aims to revolutionize sublingual drug delivery.","length":548,"tagName":"p"},{"type":"text","content":"Key Features of Aspire's Sublingual Drug Delivery Platform","length":62,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Rapid absorption through sublingual blood vessels directly, bypassing first-pass metabolic processes","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Faster onset of action","length":22,"tagName":"p"}]},{"val":[{"type":"text","content":"Sublingual route avoids exposing the drug to the...

More updates from Aspire Biopharma Holdings, Inc.